NCT07169721 (CIRCA-IMMAX) is a clinical trial in Healthy Subjects, sponsored by Leibniz Research Centre for Working Environment and Human Factors.

Who is sponsoring NCT07169721?

NCT07169721 is sponsored by Leibniz Research Centre for Working Environment and Human Factors.

What condition does NCT07169721 study?

NCT07169721 studies Healthy Subjects, Immune Cells (Mucosal and Systemic).

Is NCT07169721 still recruiting?

NCT07169721 is currently completed. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT07169721: CIRCA-IMMAX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CIRCAdian Rhythm of the IMMune Age IndeX (IMMAX)

Completed Last updated 17 September 2025

What this trial tests

trial in Healthy Subjects in 50 participants. Completed in 22 April 2024.

Timeline

1 December 2023

Primary endpoint
28 March 2024

22 April 2024

Quick facts

Lead sponsor	Leibniz Research Centre for Working Environment and Human Factors
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 December 2023
Primary completion	28 March 2024
Estimated completion	22 April 2024
Sites	1 location across Germany

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →
Immune Cells (Mucosal and Systemic) — all drugs for Immune Cells (Mucosal and Systemic) →

Sponsor

Leibniz Research Centre for Working Environment and Human Factors

Who can join

18 and older, any sex, with Healthy Subjects or Immune Cells (Mucosal and Systemic). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate the influence of circadian rhythms on the determination of an individual's immune age. The biomarker IMMAX was calculated for 50 participants aged 20-69 at 8 a.m., 1 p.m. and 6 p.m. on the same day.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07169721 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leibniz Research Centre for Working Environment and Human Factors
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07169721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing